BVA

Fairgen raises $8M for statistically accurate AI-generated survey responses

Retrieved on: 
Jeudi, mai 9, 2024
TEL, AI, Statistics, Partnership, Doctor of Philosophy, Meta, Research, Mathematics, Stanford University, General partnership, Human, BVA, Medical device

TEL AVIV, Israel, May 9, 2024 /PRNewswire/ -- Fairgen, the company generating accurate AI responses to surveys, has raised $8 million to date in Seed funding, led by Maverick Ventures Israel, with participation from Tal Ventures, IGNIA and Creator Fund to move consumer insights into the AI era. The company is launching FairBoost, its flagship solution that doubles the size of under-sampled segments using predictive synthetic responses.

Key Points: 
  • The company is launching FairBoost, its flagship solution that doubles the size of under-sampled segments using predictive synthetic responses.
  • In some cases, researchers must go back and pay a premium to collect more responses from underrepresented groups in the study.
  • The model learns the relationship between the different surveyed groups and can extrapolate from the larger groups, generating new responses for niche groups in minutes that are mathematically guaranteed to be statistically accurate.
  • Fairgen was founded by Samuel Cohen, a former research scientist at Meta, and serial entrepreneurs Benny Schnaider & Michael Cohen.

Travis Hess to Join BigCommerce as Company President

Retrieved on: 
Lundi, mai 6, 2024
Online Retail, Technology, Payments, Specialty, Electronic Commerce, Fashion, Security, Retail, Software, Internet, Home Goods, The Stables, Salesforce, BIGC, PlayStation Vita system software, DTC, Ecosystem, Commerce, GTM, Annual report, Security (finance), Partnership, Software as a service, Rackspace Technology, DNA, Demandware, B2B, Stable, Pleasure, Accenture, BVA

BigCommerce (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands and retailers, today announced the company has hired veteran ecommerce and technology industry leader Travis Hess as its president.

Key Points: 
  • BigCommerce (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands and retailers, today announced the company has hired veteran ecommerce and technology industry leader Travis Hess as its president.
  • “Having spent nearly two decades in the enterprise ecommerce ecosystem, I've long admired BigCommerce's open platform and product strategy,” noted Hess.
  • He has deep knowledge of every platform’s capabilities and vulnerabilities, and he believes BigCommerce is the best enterprise platform on the market.
  • BigCommerce has also strengthened its sales team with the addition of Thom Armstrong as vice president of Americas enterprise sales.

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

Retrieved on: 
Mardi, avril 16, 2024
Duke University Hospital, American Heart Journal, American College, Congestion, Research, Baptist Memorial Hospital, Proxy, Heart failure, Pressure, Patient, BVA, Volume analysis, Letter, HF, Systemic, Medical imaging

Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA.

Key Points: 
  • Data Presented at the American College of Cardiology Scientific Sessions;
    Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients.
  • Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA.
  • “These studies add to the numerous research papers and trials reporting the value of BVA at measuring congestion to improve outcomes,” stated Jonathan Feldschuh, Daxor’s Chief Scientific Officer.
  • A research letter published in the American Heart Journal, titled, ‘Prognostic Implications of Volume Status Assessed by Blood Volume Analysis in Ambulatory Heart Failure,’ was authored by leading heart failure experts from Duke University Medical Center, Baptist Memorial Hospital and Banner University Medical Center.

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)

Retrieved on: 
Lundi, avril 15, 2024
Atlanta Marriott Marquis, Mortality, American College, Conference, Length of stay, American College of Cardiology, BVA, Pharmaceutical industry

Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from across the country to transform cardiovascular care, featuring interactive industry-leading education designed for the MedAxiom membership community.

Key Points: 
  • The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from across the country to transform cardiovascular care, featuring interactive industry-leading education designed for the MedAxiom membership community.
  • “MedAxiom’s spring conference provides an important opportunity to highlight our BVA diagnostic to cardiovascular leaders and innovators.
  • Our aim is to demonstrate how our unique technology directly tackles issues such as readmissions, mortality, and resource optimization.
  • These healthcare systems acknowledge MedAxiom as a leader in introducing solutions that improve outcomes, lower expenses, and enhance patient well-being,” said Michael Feldschuh, CEO and President of Daxor.

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

Retrieved on: 
Mercredi, avril 10, 2024
Mortality, Hospital, BVA

Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the purchase of Daxor’s BVA-100™ at a 450-bed teaching hospital in the greater Chicago area.

Key Points: 
  • Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the purchase of Daxor’s BVA-100™ at a 450-bed teaching hospital in the greater Chicago area.
  • “Hospitals are utilizing our BVA diagnostic to save money by reducing length of stay while improving Hospital Readmissions Reduction Program (HRRP) quality metrics such as 30-day readmissions and mortality,” noted Jonathan Feldschuh, Daxor’s Chief Scientific Officer.
  • “The upward momentum in our sales continues with this latest commercial win.
  • “We are on track to secure contracts with two additional hospitals in the Chicago area, maintaining our positive sales growth and successful start to the year.”

Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24

Retrieved on: 
Lundi, avril 1, 2024
Cardiology, Congress Center, BVA, American College, Booth

Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024.

Key Points: 
  • Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024.
  • “ACC.24 is considered the premier cardiology exposition in the Americas, offering a prime opportunity for Daxor to broaden its reach within the entire cardiovascular community,” said Michael Feldschuh, Daxor’s CEO and President.
  • “This conference presents an ideal platform for engaging with healthcare providers for whom effective volume management poses a significant challenge.
  • Our blood volume analysis (BVA) technology provides 98% accurate, actionable data to optimize treatment plans and personalize care, improving outcomes while reducing duration and cost of care.”
    The Company will be exhibiting at Booth #2312.

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Retrieved on: 
Lundi, mars 25, 2024
GFR, Commercialization, BVA, Customer experience, Iodine (125I) human albumin, Glomerular filtration rate, Blood volume, Pharmaceutical industry

Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base.

Key Points: 
  • Daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing.
  • This is due to the embedded revenue streams of the drugs and significantly higher margins that will be achieved with internalized production.
  • No payments will come due until manufacturing is fully transitioned to Daxor over the next 6-9 months.
  • The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Lundi, mars 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

Bravada Gold Corp. Invites You to PDAC 2024 in Toronto

Retrieved on: 
Jeudi, février 29, 2024
Prospectors, Booth, MTCC, BVA, PDAC, Metro Toronto Convention Centre

Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Visit Bravada Gold Corp. (TSXV: BVA) (OTCQB: BGAVF) at Booth #2451 at the Prospectors & Developers Association of Canada’s (PDAC) Convention at the Metro Toronto Convention Centre (MTCC) from Sunday, March 3 to Wednesday, March 6, 2024.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Visit Bravada Gold Corp. (TSXV: BVA) (OTCQB: BGAVF) at Booth #2451 at the Prospectors & Developers Association of Canada’s (PDAC) Convention at the Metro Toronto Convention Centre (MTCC) from Sunday, March 3 to Wednesday, March 6, 2024.

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

Retrieved on: 
Lundi, mars 11, 2024
Hospital, BVA, Marketing, Lab, Growth, Calendar, Trauma, Research

These new acquisitions further fuel BVA sales growth and underscore its clinical relevance.

Key Points: 
  • These new acquisitions further fuel BVA sales growth and underscore its clinical relevance.
  • New client and services wins include:
    BVA analyzer purchase at a 735-bed non-profit, tertiary, research and academic medical center located in northern New Jersey.
  • Daxor’s ezBVA Lab service extended to a regional academic medical center, Level I adult trauma center in Ohio.
  • “We remain focused on commercialization - broadening our reach with new analyzer sales, while driving increased utilization within our current customer base, supported by our expanding ezBVA Lab service.